Onex Canada Asset Management Inc. Lowers Stake in Johnson & Johnson $JNJ

Onex Canada Asset Management Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 22.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 9,658 shares of the company’s stock after selling 2,859 shares during the period. Onex Canada Asset Management Inc.’s holdings in Johnson & Johnson were worth $1,791,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. M Holdings Securities Inc. bought a new position in Johnson & Johnson in the third quarter valued at $2,957,000. Mcintyre Freedman & Flynn Investment Advisers Inc. lifted its stake in Johnson & Johnson by 7.4% during the third quarter. Mcintyre Freedman & Flynn Investment Advisers Inc. now owns 13,026 shares of the company’s stock worth $2,415,000 after purchasing an additional 896 shares during the last quarter. Maia Wealth LLC boosted its holdings in shares of Johnson & Johnson by 7.4% in the 3rd quarter. Maia Wealth LLC now owns 12,322 shares of the company’s stock worth $2,322,000 after purchasing an additional 845 shares in the last quarter. Main Street Research LLC increased its position in shares of Johnson & Johnson by 0.8% during the 3rd quarter. Main Street Research LLC now owns 11,385 shares of the company’s stock valued at $2,111,000 after purchasing an additional 85 shares during the last quarter. Finally, Nicolet Advisory Services LLC increased its position in shares of Johnson & Johnson by 1.0% during the 3rd quarter. Nicolet Advisory Services LLC now owns 14,847 shares of the company’s stock valued at $2,804,000 after purchasing an additional 143 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 1,322 shares of the company’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,142 shares of company stock valued at $7,360,528 in the last three months. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $241.71 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a one year low of $141.50 and a one year high of $251.71. The business’s 50 day simple moving average is $231.91 and its two-hundred day simple moving average is $206.23. The stock has a market capitalization of $582.50 billion, a P/E ratio of 21.87, a price-to-earnings-growth ratio of 2.39 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.2%. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approves the TECNIS PureSee intraocular lens, adding a new, differentiated cataract/presbyopia product to J&J’s surgical vision portfolio — could support revenue and aftermarket growth in the medtech segment. FDA Approval Of TECNIS PureSee IOL Adds New Lens For J&J Investors
• Positive Sentiment: Promising Phase 1 Erda‑iDRS (erdafitinib) results in intermediate‑risk NMIBC: 89% complete response rate and durable responses up to 18 months with tolerable safety — bolsters oncology pipeline optionality if later‑stage data confirm benefit. Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
• Positive Sentiment: BofA raised its price target (to $253) and lifted revenue expectations citing pipeline growth — supportive analyst attention that can underpin sentiment even with a Neutral rating. BofA Raises Johnson & Johnson (JNJ) Price Target on Pipeline Growth
• Positive Sentiment: Citigroup analyst expects JNJ shares to rise — additional buy-side commentary can amplify positive flows if confirmed with upgrades or higher targets. Johnson & Johnson (NYSE:JNJ) Stock Price Expected to Rise, Citigroup Analyst Says
• Neutral Sentiment: Dividend and “Dividend King” coverage reminds investors of JNJ’s income profile — supportive for long‑term holders but unlikely to drive short‑term price swings. Johnson & Johnson (JNJ) Could Be a Great Choice
• Neutral Sentiment: Barclays reaffirmed its Hold rating — steady analyst stance that tempers upside momentum from positive news. Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
• Neutral Sentiment: Industry pieces on BCG shortages and competitor ImmunityBio note market dynamics in NMIBC — useful context for future demand shifts but not an immediate JNJ catalyst. IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking
• Neutral Sentiment: Analyst / valuation updates show modest shifts in fair value assumptions tied to individual drugs (Tremfya, Tecvayli, Inlexzo, Darzalex) — indicates ongoing re‑rating risk/reward as pipeline readouts arrive. How The Johnson & Johnson (JNJ) Narrative Is Shifting With Pipeline Rethinks And New Valuation Targets
• Negative Sentiment: Preliminary approval of a $65M eve‑of‑trial settlement in an antitrust suit tied to Actelion’s Tracleer — modest direct financial hit but reputational/legal overhang for the pharma legacy business. Eve-of-Trial $65M Settlement Preliminarily Approved in Novel Antitrust Class Action Against J&J Subsidiary Actelion Pharmaceuticals

Wall Street Analyst Weigh In

A number of analysts recently weighed in on JNJ shares. BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Thursday, March 5th. Leerink Partners boosted their price objective on shares of Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a report on Thursday, January 22nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. Finally, Morgan Stanley set a $262.00 target price on shares of Johnson & Johnson and gave the company an “overweight” rating in a report on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.91.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.